Teclistamab is now an option after progression on triple-class therapy; however, the FDA also issued a Boxed Warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity.
A Qualitative Research Study accomplished by Data Bridge Market research titled “Blood Plasma Market” with 100+ market data Tables, Pie Charts, Graphs & Figures
A Qualitative Research Study accomplished by Data Bridge Market research titled Blood Plasma Market with 100+ market data Tables, Pie Charts, Graphs & Figures
Researchers at Koç University discovered why a promising class of cancer treatments fail, and their findings point to how such treatments might be made to work.
Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.